Global Vaccine Partnering Terms and Agreements 2010-2016: Deal trends, players and financials

The Global Vaccine Partnering Terms and Agreements 2010-2016: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in vaccine and adjuvant partnering deals
Deal terms analysis
Partnering agreement structure
Partnering contract documents
Top deals by value
Most active dealmakers
Average deal terms for vaccines

This report contains a comprehensive listing of all vaccine partnering deals announced since January 2010, including financial terms where available, including over 1,000 links to online deal records of actual vaccine partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The report takes readers through the vaccine deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering vaccine partnering deals.

Full Report Details at
- http://www.fastmr.com/prod/1151737_global_vaccine_partnering.aspx?afid=301

The report presents average financial deal terms values for vaccine deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The middle section of the report explores the leaders in the vaccine partnering field; both the leading deal values and leading players are reported allowing readers to see who is succeeding in this growing market. This chapter also looks at the contributions by the big pharma and big biotech companies of the world in terms of deals made.

One of the key highlights of the report is that over 1,000 online deals records of actual vaccine deals as disclosed by the deal parties are included towards the end of the report in a directory format that is easy to reference. Each deal links via Weblink to an online version and all these deals are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy and technology focus. In addition the report includes actual contract documents where available as submitted to the Securities Exchange Commission by companies and their deal partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Finally the report concludes by looking into the future of vaccine partnering. With so many innovators looking for the next big thing in the field, the report selects companies to watch who are predicted to become big in the field based on their current dealmaking and financial trends.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Global Cancer Vaccine Partnering 2010-2016: Deal trends, players, financials and forecasts
- Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials
- Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2010-2016: Deal trends, players and financials
- Global Monoclonal Antibody Partnering Terms and Agreements 2010-2016: Deal trends, players and financials
- Global Oncology Partnering 2010-2016: Deal trends, players and financials